VYNE Therapeutics (VYNE) Competitors $1.00 -0.15 (-13.04%) Closing price 04:00 PM EasternExtended Trading$1.05 +0.05 (+5.10%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. ADAP, GNTA, XCUR, CTMX, TELO, EPIX, STRO, PYXS, JSPR, and IGMSShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Adaptimmune Therapeutics (ADAP), Genenta Science (GNTA), Exicure (XCUR), CytomX Therapeutics (CTMX), Telomir Pharmaceuticals (TELO), ESSA Pharma (EPIX), Sutro Biopharma (STRO), Pyxis Oncology (PYXS), Jasper Therapeutics (JSPR), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Adaptimmune Therapeutics Genenta Science Exicure CytomX Therapeutics Telomir Pharmaceuticals ESSA Pharma Sutro Biopharma Pyxis Oncology Jasper Therapeutics IGM Biosciences VYNE Therapeutics (NASDAQ:VYNE) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends. Does the MarketBeat Community prefer VYNE or ADAP? Adaptimmune Therapeutics received 293 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. However, 67.92% of users gave VYNE Therapeutics an outperform vote while only 63.39% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformVYNE TherapeuticsOutperform Votes3667.92% Underperform Votes1732.08% Adaptimmune TherapeuticsOutperform Votes32963.39% Underperform Votes19036.61% Is VYNE or ADAP more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to VYNE Therapeutics' net margin of -6,896.55%. VYNE Therapeutics' return on equity of -43.73% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-6,896.55% -43.73% -38.55% Adaptimmune Therapeutics -25.43%-74.15%-15.09% Which has preferable valuation and earnings, VYNE or ADAP? VYNE Therapeutics has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$605K25.14-$28.45M-$0.99-1.01Adaptimmune Therapeutics$178.03M0.40-$113.87M-$0.27-1.02 Which has more volatility & risk, VYNE or ADAP? VYNE Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Do institutionals & insiders hold more shares of VYNE or ADAP? 83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 4.8% of VYNE Therapeutics shares are held by insiders. Comparatively, 12.7% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer VYNE or ADAP? In the previous week, Adaptimmune Therapeutics had 16 more articles in the media than VYNE Therapeutics. MarketBeat recorded 16 mentions for Adaptimmune Therapeutics and 0 mentions for VYNE Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.11 beat VYNE Therapeutics' score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment VYNE Therapeutics Neutral Adaptimmune Therapeutics Neutral Do analysts prefer VYNE or ADAP? VYNE Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 525.00%. Adaptimmune Therapeutics has a consensus price target of $1.52, suggesting a potential upside of 452.12%. Given VYNE Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe VYNE Therapeutics is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Adaptimmune Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummaryAdaptimmune Therapeutics beats VYNE Therapeutics on 10 of the 18 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.21M$6.49B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-1.168.9326.5819.71Price / Sales25.14251.28391.69116.98Price / CashN/A65.8538.2534.62Price / Book0.166.466.794.50Net Income-$28.45M$143.98M$3.23B$248.18M7 Day Performance-20.63%3.02%4.03%1.14%1 Month Performance-44.13%7.45%12.50%15.19%1 Year Performance-62.96%-2.42%16.73%6.55% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics1.9755 of 5 stars$1.00-13.0%$6.25+525.0%-57.9%$15.21M$605,000.00-1.1630High Trading VolumeADAPAdaptimmune Therapeutics2.7799 of 5 stars$0.30+0.9%$1.83+519.9%-73.9%$75.94M$178.03M-1.34490GNTAGenenta Science1.5102 of 5 stars$4.13-5.0%$25.00+506.1%+43.4%$75.45MN/A0.007XCURExicure1.4865 of 5 stars$11.86+3.7%N/A+2,046.5%$74.93M$500,000.00-5.7350Gap UpCTMXCytomX Therapeutics4.2485 of 5 stars$2.13+129.4%$4.25+99.5%+7.3%$74.85M$138.10M12.53170Analyst RevisionGap DownHigh Trading VolumeTELOTelomir Pharmaceuticals1.7562 of 5 stars$2.51+0.8%$15.00+497.6%-62.1%$74.71MN/A-4.331Gap UpEPIXESSA Pharma2.0451 of 5 stars$1.68-2.3%$9.50+465.5%-73.6%$74.57MN/A-2.4350News CoveragePositive NewsSTROSutro Biopharma4.4181 of 5 stars$0.87-0.2%$6.63+661.5%-80.8%$73.40M$62.04M-0.54240News CoverageAnalyst ForecastGap DownPYXSPyxis Oncology1.445 of 5 stars$1.15+7.5%$9.00+682.6%-71.1%$71.24M$16.15M-1.1260Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownJSPRJasper Therapeutics2.1579 of 5 stars$4.74+4.9%$62.50+1,218.6%-78.3%$71.20MN/A-1.0020IGMSIGM Biosciences4.0115 of 5 stars$1.19+5.3%$5.50+362.2%-85.2%$71.13M$2.68M-0.33190Positive NewsGap Down Related Companies and Tools Related Companies ADAP Competitors GNTA Competitors XCUR Competitors CTMX Competitors TELO Competitors EPIX Competitors STRO Competitors PYXS Competitors JSPR Competitors IGMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VYNE Stock Free VYNE Stock Alerts